Quantum BioPharma partners with Allucent for multiple sclerosis trial

March 30, 2026 7:50 AM

Quantum BioPharma Ltd. (NASDAQ: QNTM) entered into a binding letter of intent with Allucent to conduct a Phase 2 clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found